R01AG074008
Project Grant
Overview
Grant Description
Impact of sex differences in immune function on shared risk for cardiometabolic disorder & Alzheimer's disease - summary
By 2050, approximately 13.8 million people in the U.S. are projected to have Alzheimer's disease (AD), two-thirds of whom will be women.
Secondary to genetics, cardiometabolic diseases (CMD), such as hypertension and diabetes, are major independent risk factors for AD.
There are significant sex differences in pathology, timing, and clinical presentation of these diseases in early midlife.
Despite this, the shared pathophysiology underlying CMD and AD, and sex differences therein, are largely unexplored.
Here, we will test the hypothesis that sex differences in immune pathophysiology, in part, underlies the sex-dependent impact of cardiometabolic dysfunction on AD risk in midlife.
We propose to recruit 240 people, ages 50-75, equally divided by sex, that are “high and low risk” (HR & LR) for AD, defined as those with genetic risk and CMD vs. those without.
Currently, we are recruiting 100 people (ages 50-70), whom we will re-recruit in the current study at ages 55-75.
We will develop a general AD polygenic risk score (PRS) and a sex-stratified PRS to select HR and LR individuals along with presence or absence of CMD.
We are conducting extensive in-clinic assessments to characterize structural and functional MRI (S/fMRI), cognitive function, hormone and immune profiling, cardiophysiology, neurovascular structure/function, genotype, RNA transcription and cell metabolism of monocyte cells, Aβ PET imaging, and AD blood-based biomarkers.
Here, we propose to recruit an additional 140 HR and LR subjects, equally divided by sex, in order to obtain adequate statistical power to test for the shared sex-dependent impact of immune dysregulation underlying the association between CMD and AD-related pathology.
Further, we will follow the current 100 subjects to evaluate the longitudinal impact of immune dysregulation on 5-year change in AD-related pathology by sex.
We predict that HR vs. LR individuals will express significantly greater AD-related pathology [blood-based & PET AD biomarkers and memory circuitry deficits in entorhinal cortex, temporoparietal, cingulate, medial prefrontal cortex, locus coeruleus, and paraventricular hypothalamic nucleus], metabolic and neurovascular deficits, and dysregulation of immune pathway genes, cellular metabolism, and increased pro-inflammatory markers, with postmenopausal women worse than men.
Further, we predict immune dysregulation will mediate (i.e., in part, explain) the relationship between HR vs. LR and AD-related pathology, and that this mediation will be stronger (larger effect sizes) in postmenopausal women versus men.
Finally, in exploratory analyses, we predict that the presence of CMD will exacerbate the effects of genetic risk alone on AD-related pathology, with women experiencing worse outcomes than men.
Overall, identifying sex-dependent mechanisms will have substantial implications for developing neuroimmune therapeutics that may differ by sex and targeted early for prevention.
By 2050, approximately 13.8 million people in the U.S. are projected to have Alzheimer's disease (AD), two-thirds of whom will be women.
Secondary to genetics, cardiometabolic diseases (CMD), such as hypertension and diabetes, are major independent risk factors for AD.
There are significant sex differences in pathology, timing, and clinical presentation of these diseases in early midlife.
Despite this, the shared pathophysiology underlying CMD and AD, and sex differences therein, are largely unexplored.
Here, we will test the hypothesis that sex differences in immune pathophysiology, in part, underlies the sex-dependent impact of cardiometabolic dysfunction on AD risk in midlife.
We propose to recruit 240 people, ages 50-75, equally divided by sex, that are “high and low risk” (HR & LR) for AD, defined as those with genetic risk and CMD vs. those without.
Currently, we are recruiting 100 people (ages 50-70), whom we will re-recruit in the current study at ages 55-75.
We will develop a general AD polygenic risk score (PRS) and a sex-stratified PRS to select HR and LR individuals along with presence or absence of CMD.
We are conducting extensive in-clinic assessments to characterize structural and functional MRI (S/fMRI), cognitive function, hormone and immune profiling, cardiophysiology, neurovascular structure/function, genotype, RNA transcription and cell metabolism of monocyte cells, Aβ PET imaging, and AD blood-based biomarkers.
Here, we propose to recruit an additional 140 HR and LR subjects, equally divided by sex, in order to obtain adequate statistical power to test for the shared sex-dependent impact of immune dysregulation underlying the association between CMD and AD-related pathology.
Further, we will follow the current 100 subjects to evaluate the longitudinal impact of immune dysregulation on 5-year change in AD-related pathology by sex.
We predict that HR vs. LR individuals will express significantly greater AD-related pathology [blood-based & PET AD biomarkers and memory circuitry deficits in entorhinal cortex, temporoparietal, cingulate, medial prefrontal cortex, locus coeruleus, and paraventricular hypothalamic nucleus], metabolic and neurovascular deficits, and dysregulation of immune pathway genes, cellular metabolism, and increased pro-inflammatory markers, with postmenopausal women worse than men.
Further, we predict immune dysregulation will mediate (i.e., in part, explain) the relationship between HR vs. LR and AD-related pathology, and that this mediation will be stronger (larger effect sizes) in postmenopausal women versus men.
Finally, in exploratory analyses, we predict that the presence of CMD will exacerbate the effects of genetic risk alone on AD-related pathology, with women experiencing worse outcomes than men.
Overall, identifying sex-dependent mechanisms will have substantial implications for developing neuroimmune therapeutics that may differ by sex and targeted early for prevention.
Awardee
Funding Goals
TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Boston,
Massachusetts
021142621
United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the total obligations have increased 187% from $1,249,153 to $3,583,521.
The General Hospital Corporation was awarded
Sex Differences in Immune Function Impact on CMD & AD Risk
Project Grant R01AG074008
worth $3,583,521
from National Institute on Aging in September 2021 with work to be completed primarily in Boston Massachusetts United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.866 Aging Research.
The Project Grant was awarded through grant opportunity Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 8/20/25
Period of Performance
9/30/21
Start Date
8/31/26
End Date
Funding Split
$3.6M
Federal Obligation
$0.0
Non-Federal Obligation
$3.6M
Total Obligated
Activity Timeline
Transaction History
Modifications to R01AG074008
Additional Detail
Award ID FAIN
R01AG074008
SAI Number
R01AG074008-2458774070
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NN00 NIH National Insitute on Aging
Funding Office
75NN00 NIH National Insitute on Aging
Awardee UEI
FLJ7DQKLL226
Awardee CAGE
0ULU5
Performance District
MA-08
Senators
Edward Markey
Elizabeth Warren
Elizabeth Warren
Modified: 8/20/25